HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Plans To Upgrade Recalled OTCs for Relaunch

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson plans to return recalled OTC drugs to the market with innovations designed to strengthen consumer trust, VP of Finance and CFO Dominic Caruso said during a presentation at the Deutsche Bank Securities Health Care Conference.

You may also be interested in...

OTC Industry Standardizes Pediatric Liquid Acetaminophen Concentration

Over-the-counter drug firms will make single-ingredient liquid acetaminophen pediatric products only in one standard concentration to help prevent dosing errors, their trade association said May 4.

FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing

FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.

McNeil OTC Recalls Slice $900M From J&J's 2010 Sales

Recalled OTC drugs took a $900 million bite out of Johnson & Johnson's fiscal 2010 sales, including $300 million in the fourth quarter, contributing to what the company and analysts labeled disappointing earnings.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts